Impact Factor 3.709 | CiteScore 2.7
More on impact ›

OPINION article

Front. Public Health, 28 July 2020 | https://doi.org/10.3389/fpubh.2020.00393

Improving Non-specific Immunity to Coronavirus Disease (COVID-19) by the Novelty, Diversity, and Quantity of Antigen

Patrice Boucher1* and Roger Boucher2
  • 1Software and Information Technology Engineering Department, École de Technologie Supérieure, Montréal, QC, Canada
  • 2Médicentre, LaSalle, QC, Canada

The Objective: Save Lives

The health crisis caused by the COVID-19 pandemic continues to claim thousands of lives around the world. The current challenge for the scientific community, along with governments, is to quickly find solutions to save lives and limit the consequences of the crisis.

The scientific community is currently tackling the problem primarily by aiming to develop a vaccine to enable the body to develop an antigen-specific immune response to COVID-19. This approach requires time-consuming studies in order to understand the underlying properties of COVID-19 and to deploy the vaccine (1), which is very challenging to achieve at pandemic speed (2). Moreover, it could be compromised by mutations in the COVID-19 genome (3).

However, it is essential to note that the problem could be approached from at least one other front for more rapid deployment in a pandemic context. Too little consideration has been devoted to the roles of the non-specific immune response via natural killer (NK) cells, which continue to be neglected in research into vaccines (4).

An Alternative Approach: Exploiting The Action Of NK Cells

NK cells are involved in innate resistance that is not antigen-specific, but these cells also play roles in adaptive immunity by favoring the development of antigen-specific T helper (Th) type 1 cells by producing IFN-γ and IL-2 (57). In other words, a better NK effector cell response [via the production of IFN-γ and the exocytosis of cytotoxic granules (4)] directly contributes to virus neutralization and to the efficiency by which specific antigens are developed at the time of infection. During an infection, NK cells also specialize as memory NK cells, which mediate protection against a second infection by the same pathogen (4, 8). The ability of these memory cells to mediate protection against other pathogens should therefore be further investigated.

Since the beginning of the pandemic, children have presented the highest resistance to COVID-19, but this resistance gradually decreases with age (9). In the first phase of infection, the innate immune system of children typically neutralizes the virus, but this is ineffective in the older population, which commonly lacks NK cells during this phase (10). The depletion of NK cells correlates with the severity of infections (10, 11). Therefore, the perspective of enhancing the response of the non-specific immune system should be seriously investigated in the context of this pandemic.

Improving Immunity To COVID-19

Horowitz et al. (4) demonstrated that vaccination enhances NK cell effector responses in an antigen-specific manner for a fairly long period of time (their tests were conducted after about 4 months), which agrees with the documented properties of memory NK cells (8). Hence, if multiple vaccines enhance the NK effector response with diverse memory NK cells, this suggests that they may significantly contribute to (i) the neutralization of the COVID-19 pathogen, and (ii) the development of specific antibodies at the time of infection.

Children experience many novel antigens via vaccines, influenza, and other environmental pathogens. The speed by which NK cells neutralize the pathogen, as seen in children, is the main factor limiting its propagation in the body. The literature shows that the response of the immune system can be trained by episodic infections. We propose the hypothesis that the novelty, diversity, and quantity of antigen could play a key role in training the non-specific immune system to evoke a fast, efficient response to pathogens.

In order to test this hypothesis, we aim to reproduce the experience of children with many diverse and potentially novel antigens, before analyzing the effects of such experiences on the immune system. The complexity of this task should require numerous research projects, giving rise to a new avenue for research in immunology. Nevertheless, this could be investigated in the first instance by the revaccination of older people with a set of vaccines administered to young children. For the novelty of antigen, the use of vaccines that are new to a target population (e.g., existing vaccines in foreign countries) could also be studied. In such a study, a group of vaccinated subjects and a group of demographically equivalent non-vaccinated subjects should be periodically tested for COVID-19. If vaccination effectively improves non-specific immunity, the infected subjects of the vaccinated group should be less severely infected on average (including lower morbidity and more asymptomatic cases) than the infected subjects in the non-vaccinated group. Here, an improvement in non-specific immunity is expected, in particular, if (i) an increased concentration of NK cells is observed and lasts for several months/years; (ii) these NK cells (including primitive NK cells and memory NK cells developed in response to vaccination) are effective against new antigens; and (iii) they accelerate the development of antibodies.

It is worth mentioning that vaccines have shown to be less effective on older people, who are subject to immunosenescence (12). In spite of the adverse events reported, e.g., by the Vaccine Adverse Event Reporting System (VAERS) in the U.S., several vaccines have proven to be secure and relevant for adults and older people including, for example, the vaccines for measles, mumps, and rubella (13); influenza (14); pneumococcal conjugate with PCV13 and PCV23 (15); tetanus toxoid, reduced diphtheria, and acellular pertussis (16, 17); herpes zoster (18); and acute upper respiratory tract infection with the Bacillus Calmette-Guérin vaccine (19, 20), which is also under study for improving immunity to COVID-19 (21).

Yu et al. (22) analyzed the effect of childhood vaccinations on cross-reactivity against SARS-CoV in mice by evaluating the ability of T cells to recognize the SARS-CoV antigen in vaccinated compared to unvaccinated mice. They did not observe a significant difference between the two groups. Their conclusion was that “the reduced symptoms among children infected by SARS-CoV may be caused by other factors [than vaccination]”; however, this ignores the effects of the non-specific immune system via NK cells. First, as suggested by Horowitz et al. (4), vaccines given to children could be rather beneficial by improving the response of NK cells. Second, given the interspecies differences in NK cell activity (23), we do not know whether NK cells neutralize the virus prior to the development of specific antibodies.

Conclusion

We propose the hypothesis that the novelty, diversity, and quantity of antigen could play a key role in training the non-specific immune system for a fast, efficient response to pathogens. If true, it is expected that vaccination with existing vaccines could help vulnerable populations to fight the virus more effectively. This hypothesis should be seriously considered since:

• It is supported by the recently documented action of the non-specific immune system via NK cells, and is coherent with clinical observations (despite the fact that they are still not sufficient to validate it). For example, this hypothesis would explain why children are more resistant to COVID-19 and why immunity gradually decreases with age.

• This could mean that thousands of lives can be saved quickly.

It could be addressed empirically by a statistical analysis of the occurrence of COVID-19 and severity in a targeted population in which we administer a set of existing vaccines. This approach could also be tested in resource-restricted settings. Most countries around the world, including developing countries, currently have access to many low-cost vaccines (24).

Given the urgency of the situation, we recommend that the scientific community, in cooperation with governments, rapidly investigate this hypothesis. Such a study would be quick, easy, and inexpensive to perform, with little risk to the population as the effects of existing vaccines are already known and validated.

Author Contributions

RB initiated the proposal ideas. PB developed the ideas and prepared the proposal with the support of RB. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors wish to acknowledge the editor and the reviewers of Frontiers for their constructive comments that contribute to the relevance and the quality of the paper; Virginie Grenier-Deschênes, Christine Boucher, and Proof-Reading-Service.com for proofreading.

References

1. Le TT, Andreadakis Z, Kumar A, Roman RG, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. (2020) 19:305–6. doi: 10.1038/d41573-020-00073-5

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. (2020) 382:1969–73. doi: 10.1056/NEJMp2005630

PubMed Abstract | CrossRef Full Text | Google Scholar

3. van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, et al. (2020). Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol. 83:104351. doi: 10.1016/j.meegid.2020.104351

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Horowitz A, Behrens RH, Okell L, Fooks AR, Riley EM. NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination. J Immunol. (2010) 185:2808–18. doi: 10.4049/jimmunol.1000844

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Trinchieri G. Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol. (1995) 7:83–8. doi: 10.1006/smim.1995.0012

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Romagnani S. Induction of TH1 and TH2 responses: a key role for the ‘natural' immune response? Immunol Today. (1992) 13:379–81.

PubMed Abstract | Google Scholar

7. Scott P, Trinchieri G. The role of natural killer cells in host-parasite interactions. Curr Opin Immunol. (1995) 7:34–40.

PubMed Abstract | Google Scholar

8. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature. (2009) 457:557–61. doi: 10.1038/nature07665

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. (2020) 109:1088–95. doi: 10.1111/apa.15270

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. (2020) 17:533–5. doi: 10.1038/s41423-020-0402-2

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Ebbo M, Gérard L, Carpentier S, Vély F, Cypowyj S, Farnarier C, et al. Low circulating natural killer cell counts are associated with severe disease in patients with common variable immunodeficiency. EBioMedicine. (2016) 6:222–30. doi: 10.1016/j.ebiom.2016.02.025

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Goronzy J, Weyand C. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. (2013) 14:428–36. doi: 10.1038/ni.2588

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT. Adverse events following measles, mumps, and rubella vaccine in adults reported to the vaccine adverse event reporting system (VAERS), 2003-2013. Clin Infect Dis. (2015) 60:e58–65. doi: 10.1093/cid/civ061

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Manzoli L, Salanti G, De Vito C, Boccia A, Ioannidis JP, Villari P. Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. Lancet Infect Dis. (2009) 9:482–92. doi: 10.1016/S1473-3099(09)70153-7

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Kraicer-Melamed H, O'Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine. (2016) 34:1540–50. doi: 10.1016/j.vaccine.2016.02.024

CrossRef Full Text | Google Scholar

16. Moro PL, Yue X, Lewis P, Haber P, Broder K. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010. Vaccine. (2011) 29:9404–8. doi: 10.1016/j.vaccine.2011.05.100

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Weston WM, Friedland LR, Wu X, Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine Boostrix(®): results of two randomized trials. Vaccine. (2012) 30:1721–8. doi: 10.1016/j.vaccine.2011.12.055

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Gnann JW Jr. Vaccination to prevent herpes zoster in older adults. J Pain. (2008) 9(Suppl. 1):S31–6. doi: 10.1016/j.jpain.2007.10.007

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Wardhana Datau EA, Sultana A, Mandang VV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Medica Indonesia. (2011) 43:185–90.

PubMed Abstract | Google Scholar

20. Turnbull FM, McIntyre PB, Achat HM, Wang H, Stapledon R, Gold M, Burgess MA. National study of adverse reactions after vaccination with bacille Calmette-Guérin. Clin Infect Dis. (2002) 34:447–53. doi: 10.1086/338462

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Redelman-Sidi G. Could BCG be used to protect against COVID-19? Nat Rev Urol. (2020) 17:316–7. doi: 10.1038/s41585-020-0325-9

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Yu Y, Jin H, Chen Z, Qingling LY, Ma YJ, Sun XL, et al. Children's vaccines do not induce cross reactivity against SARS-CoV. J Clin Pathol. (2007) 60:208–11. doi: 10.1136/jcp.2006.038893

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Haley PJ. Species differences in the structure and function of the immune system. Toxicology. (2003) 188:49–71. doi: 10.1016/s0300-483x(03)00043-x

PubMed Abstract | CrossRef Full Text | Google Scholar

24. World Health Organization. Global and Regional Immunization Profile. Who Vaccine-Preventable Disease Monitoring System. (2019).

Google Scholar

Keywords: coronavirus, COVID-19, natural killer cells, vaccination, non-specific immunity, pandemic crisis

Citation: Boucher P and Boucher R (2020) Improving Non-specific Immunity to Coronavirus Disease (COVID-19) by the Novelty, Diversity, and Quantity of Antigen. Front. Public Health 8:393. doi: 10.3389/fpubh.2020.00393

Received: 12 May 2020; Accepted: 06 July 2020;
Published: 28 July 2020.

Edited by:

Zisis Kozlakidis, International Agency For Research On Cancer (IARC), France

Reviewed by:

Kohei Fujita, National Hospital Organization Kyoto Medical Center, Japan
Xiaojiong Jia, Harvard Medical School, United States

Copyright © 2020 Boucher and Boucher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Patrice Boucher, patrice.boucher.qc@gmail.com